skip to Main Content

Researchers Identify Immunologic Basis of ‘Exceptional Survival’ in Pancreatic Cancer

Researchers Identify Immunologic Basis of ‘Exceptional Survival’ in Pancreatic Cancer
Patients with pancreatic cancer who had tumors with a combination of the highest neoantigen number and the most abundant CD8-positive T-cell infiltrates survived significantly longer than those without those tumor characteristics, according to study results.

“These results are exciting — particularly in the field of pancreatic cancer, which can be a very difficult diagnosis and treatment for a patient to contend with,” Vinod P. Balachandran, MD, surgical oncologist and member of the David M. Rubenstein Center for Pancreatic Cancer Research at Memorial Sloan Kettering Cancer Center, said in a press release.  Read more . . . 


Back To Top